OncoMatch/Clinical Trials/NCT07098338
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Is NCT07098338 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Rilvegostomig and Ramucirumab for non-small cell lung cancer.
Treatment: Rilvegostomig · Ramucirumab · Dato-DXd — This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several sub-studies, each evaluating the safety, tolerability, and preliminary antitumour activity of various treatment combinations. This study will be conducted in approximately 80 centers globally across 10 countries.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) tumor cell expression ≥ 50% (TC ≥ 50%)
PD-L1 TC ≥ 1% (TC≥ 50% for sub-study 1, 1-49% for sub-study 2)
Required: PD-L1 (CD274) tumor cell expression 1-49% (TC 1-49%)
PD-L1 TC ≥ 1% (TC≥ 50% for sub-study 1, 1-49% for sub-study 2)
Required: EGFR sensitizing mutation
Absence of sensitizing EGFR mutations
Required: ALK rearrangement
Absence of ... ALK rearrangements
Disease stage
Metastatic disease required
Performance status
WHO/ECOG 0–1
Prior therapy
Must have received: targeted therapy
had progressed on prior targeted therapy
Cannot have received: systemic chemotherapy
Receipt of prior systemic chemotherapy/chemoradiation/immunotherapy for advanced NSCLC for sub-study 1 and sub-study 2.
Cannot have received: chemoradiation
Receipt of prior systemic chemotherapy/chemoradiation/immunotherapy for advanced NSCLC for sub-study 1 and sub-study 2.
Cannot have received: immunotherapy
Receipt of prior systemic chemotherapy/chemoradiation/immunotherapy for advanced NSCLC for sub-study 1 and sub-study 2.
Cannot have received: immune-mediated therapy
Prior exposure to immune-mediated therapy
Lab requirements
Blood counts
Kidney function
Liver function
Adequate bone marrow and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Santa Monica, California
- Research Site · Santa Rosa, California
- Research Site · Atlanta, Georgia
- Research Site · Baltimore, Maryland
- Research Site · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify